Family office · 9 deals
Every published round UniSuper took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies UniSuper has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Aravax | 28 Jan 2024, Series B | 1 | 0 | |
| Celosia Therapeutics | 8 Oct 2025, Series A | 1 | 0 | |
| Diraq | 25 Jun 2024, Series A | 1 | 0 | |
| Ferronova | 17 Dec 2025, Series A | 1 | 1 | |
| Judo | Jan 2021, Series D+ | 1 | 0 | |
| Kinoxis Therapeutics | 12 Aug 2024, Series B | 2 | 0 | |
| Morse Micro | 28 Nov 2022, Series B | 2 | 0 |
This is a stake in the fund itself, money that the fund's manager invests, not a stake in the fund manager.
Companies UniSuper has backed that another company then bought. An exit for the holding, not a deal UniSuper did.
| Name | Role | Sources |
|---|---|---|
| Mark Armour | Independent Director | Australian FinTech |
| Simon Hudson | Head of Equities | Startup Daily |
| John Pearce | Chief Investment Officer | Startup Daily (Tue 20 May 2025), Startup Daily (Fri 25 Mar 2022) |
Stories naming UniSuper. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Weekly digest: Firmus withdraws its planned listing, Square Peg reaches a billion-dollar close on two vehicles, MUFG clears regulators to buy Grow Inc, and Lubdub, RocketDNA, Energy Bay and Metal all raise.
Weekly roundup recording a dozen raises and acquisitions, Firmus's scheduled float, a new $50m venture fund, a founder share sale, grant winners, an accelerator intake, and an AI agent's government breach.
Also DealStreetAsia·Dealroom·This Week in Australian Startups·AFR Technology·AFR Technology·Startup Daily·AFR Technology·AFR Technology·ABC News Technology·iTnews
Melbourne dementia drug developer Kinoxis secured $6.75 million equity led by Main Sequence plus a $2.5 million Medical Research Future Fund grant via CUREator+, funding trials of its agitation and pain drug candidates.
Workforce platform Expert360 is being bought by AI hiring firm Swipejobs at a reported $16 million value, while its founder and earliest backers are set to receive nothing for their stakes.
Also Startup Daily
The US medicines regulator has granted Fast Track designation to Aravax's peanut-allergy immunotherapy PVX108, easing its development path; the Melbourne-based biotech expects Phase 2 data later in 2026.
Roundup of seven trans-Tasman raises worth $93.1m this week, headlined by IND Technology's $50m round, with LawVu also acquiring ClauseBase.
Uniseed chief executive Peter Devine departs after two decades; Monash's Alistair Hick takes over in 2026. The piece recounts Uniseed's fund history and recent stakes in ENA Respiratory and Morse Micro rounds.
Sydney chipmaker Morse Micro has banked an $88 million Series C led by Japan's MegaChips, with the national reconstruction fund and several existing backers also participating; funds will drive growth and future chip development.
Also Startup Daily·builtinsydney.au·semiiphub.com·Forbes Australia·morsemicro.com·Forbes Australia·SmartCompany·Startup Daily·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily·Forbes Australia·smallbizai.au
UniSuper adds a further $25 million to its backing of Uniseed, reaching $100 million in total support for the university research commercialisation fund; past cheques to quantum and biotech startups are recapped.
Weekly funding roundup covering eight local companies that together banked $80m, topped by twin $17m Series Bs at Safewill and Fresho, plus Celosia's $16.75m Series A and five smaller rounds.
Also Startup Daily·Startup Daily·Startup Daily·Startup Daily·Startup Daily·Startup Daily·Startup Daily·LaunchVic
Aravax has finished enrolling 95 young patients in its Phase 2 peanut-allergy immunotherapy trial across US and Australian sites, with results expected in the first half of 2026.
Weekly roundup detailing five raises across Australian and New Zealand startups — Hapana, Kinoxis Therapeutics, Appetise, Bike Matrix and Aglow — worth a combined $38.5 million, naming lead investors and planned expansion for each.
Australian biotech Kinoxis Therapeutics raised $14.5 million in Series B backing from Uniseed, UniSuper and others to fund Phase 2 trials of KNX100 for dementia-related agitation, including a new Australian study.
Weekly roundup of eight Australian funding rounds, led by Samsara Eco's $100m Series A extension; Diraq, 1Breadcrumb, Aquila, NRN, Klean, Bearhug and Sindy Labs also secured capital, and Klean won a Queensland grant.
Also TechCrunch Venture·SmartCompany·@AuManufacturing·Techboard·Startup Daily·Startup Daily·SmartCompany·Startup Daily·SmartCompany·Startup Daily·@AuManufacturing·@AuManufacturing·Forbes Australia·@AuManufacturing
Roundup of Australian manufacturing briefs: Nova Eye Medical banks $8m, Ridley buys Oceania Meat Processors, Orica sells Deer Park land for $260m, plus appointments, research projects and CSIRO program deadlines.
Breakthrough Victoria announces a $12 million investment in Aravax, part of a $66 million Series B, advancing the biotech's peanut allergy immunotherapy into phase two trials in Australia and the United States.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·@AuManufacturing·Business News Australia·@AuManufacturing·Forbes Australia·Startup News (WA)
Uniseed adds Monash and a four-university NSW collaboration, lifting its third fund by $6.75 million to $56.75 million; the article recalls past portfolio sales to Novartis, Shire and Schneider Electric.
Weekly roundup reporting nine Australian startups that together secured roughly $104 million across sports tech, semiconductors, regtech, legal automation, SaaS, edtech, agtech and biotech, with Vald's $36 million the largest.
Also Techboard
Wi-Fi HaLow chip maker Morse Micro raised a further $30 million for its Series B from Australian superannuation funds, lifting the round to $170 million; its earlier seed and Series A raises are also recapped.
Also SmartCompany·Techboard·Startup Daily·SmartCompany·Startup Daily
Australian biotech OccuRx secured $16 million co-led by Brandon BioCatalyst and Uniseed, including a CUREator grant, to advance its oral anti-fibrosis therapy into kidney disease trials; two executives also joined.
Techboard's March 2022 roundup of Australian funding: megadeals by Immutable, Saluda Medical, Linktree and Zeller, many smaller raises, acquisitions, an IPO, several fund closes, and companies still seeking capital.
UniSuper commits $75 million to Uniseed, the research commercialisation fund owned by four universities and CSIRO, its first venture investment; past portfolio sales to Schneider Electric, RTP Co and Novartis are recalled.
Hotel commerce platform SiteMinder listed on the ASX, raising $627 million and closing its debut up 38% at a $1.88 billion valuation, after a $100 million pre-IPO raise.
Also Startup Daily
Australian banking-savings app Finspo has closed a $2.7 million Series A led by angels Mark Armour and Ashok Ramamurthy, both joining its board, ahead of the app's public launch.
Also Startup Daily